PT - JOURNAL ARTICLE AU - Shuqing Lü AU - Jianmin Wang AU - Xianmin Song AU - Li Chen AU - Weiping Zhang AU - Jun Hou AU - Xiaoqian Xu AU - Chongmei Huang AU - Jianmin Yang TI - Clinical Observation of FMD Regimen: Fludarabine, Mitoxantrone, Dexamethasone, in Treatment of Non-Hodgkin's Lymphoma AID - 10.1007/s11805-008-0433-4 DP - 2008 Dec 01 TA - Chinese Journal of Clinical Oncology PG - 433--436 VI - 5 IP - 6 4099 - http://www.cancerbiomed.org/content/5/6/433.short 4100 - http://www.cancerbiomed.org/content/5/6/433.full SO - Cancer Biol Med2008 Dec 01; 5 AB - OBJECTIVE To evaluate the clinical effectivity and toxicity of the regimen FMD (fludarabine, mitoxantrone, dexamethasone) in patients with non-Hodgkin’s lymphoma.METHODS Thirty-two patients, twenty-four of whom had indolent B-cell lymphoma, 6 peripheral T-cell lymphoma, two diffuse large B-cell lymphoma, received FMD. Treatment comprised: fludarabine 25~30 mg/m2 days 1~3, mitoxantrone 8~10 mg/m2 day 1, and dexamethasone 20~30 mg/m2 days 1~5. At the same time, patients received prophylaxis against conditional infection with trimethoprim-sulfamethoxazole, fluconazole, acyclovir and immunoglobulin.RESULTS Of the thirty-two patients treated, the complete response (CR) rate, partial response (PR) rate and overall response (OR) rate were 56.3%, 21.9% and 78.2% respectively. The CR and OR rate of 24 patients with indolent B-cell lymphoma were 66.7% and 88.3% respectively. Two of six patients with peripheral T-cell lymphoma were of complete response type and one was of partial response type. One of two patients with diffuse large B-cell lymphoma was partial response. The dominating toxicity was myelotoxicity and immunotoxicity. There was no treatment associated death in all patients treated with FMD. Grade 3~4 neutropenia occurred in 43.8% patients, 12.5% patients had infections and 9.3% developed grade 3~4 thrombocytopenia. At a median follow-up of 24 (5~54) months, the 2-year overall-survival rate and progression-free survival rate were (87.5 ± 1.4)% and (83.3 ± 1.6)% respectively. The 2-year OS and PFS rates of the indolent group were (93.75 ± 6.25)% and (87.5 ± 8.54)%.CONCLUSION FMD regimen was highly effective with low toxicity in the treatment of non-Hodgkin’s lymphoma, especially in indolent B-cell lymphoma. It also helps to improve the prognosis even in some aggressive lymphoma, such as peripheral T cell lymphoma.